Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma
Authors
Keywords
-
Journal
Journal of Immunology Research
Volume 2017, Issue -, Pages 1-14
Publisher
Hindawi Limited
Online
2017-12-21
DOI
10.1155/2017/6915912
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells
- (2017) Jihao Zhou et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor
- (2017) K H Chen et al. LEUKEMIA
- Effective combinatorial immunotherapy for castration-resistant prostate cancer
- (2017) Xin Lu et al. NATURE
- Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity
- (2017) Akash Patnaik et al. Cancer Discovery
- Novel recombinant immunotoxin of EGFR specific nanobody fused with cucurmosin, construction and antitumor efficiency in vitro
- (2017) Cuimin Deng et al. Oncotarget
- Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment
- (2017) Irene Scarfò et al. Journal for ImmunoTherapy of Cancer
- Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview
- (2016) C. H. J. Lamers et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Cryopreserved NK cells in the treatment of haematological malignancies: preclinical study
- (2016) Monika Holubova et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib
- (2016) Linh Nguyen et al. JOURNAL OF CLINICAL PHARMACOLOGY
- RCC — advances in targeted therapeutics and genomics
- (2016) W. Marston Linehan et al. Nature Reviews Urology
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
- (2016) Christine E. Brown et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response
- (2016) Richard P. Junghans et al. PROSTATE
- Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies
- (2016) Kevin H. Chen et al. Oncotarget
- Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects
- (2016) Kenneth G. Liu et al. Oncotarget
- A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases
- (2016) Xilin Chen et al. Oncotarget
- ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
- (2015) Congcong Zhang et al. JNCI-Journal of the National Cancer Institute
- Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor
- (2015) Kurt Schönfeld et al. MOLECULAR THERAPY
- Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice
- (2015) Fei-Ting Hsu et al. Oncotarget
- ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
- (2015) Congcong Zhang et al. JNCI-Journal of the National Cancer Institute
- Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival
- (2015) Sabrina Genßler et al. OncoImmunology
- Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer
- (2014) Danhong Wang et al. BMC CANCER
- Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine
- (2014) Anna R Kwilas et al. Journal of Translational Medicine
- CD8+T cell–specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors
- (2014) Jiemiao Hu et al. Molecular Cancer
- A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma
- (2014) Hirokazu Matsushita et al. Journal for ImmunoTherapy of Cancer
- Doxorubicin Eliminates Myeloid-Derived Suppressor Cells and Enhances the Efficacy of Adoptive T-Cell Transfer in Breast Cancer
- (2013) D. Alizadeh et al. CANCER RESEARCH
- Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer
- (2013) Y. Homma et al. Clinical & Translational Oncology
- Strategies to Improve the Clinical Performance of Chimeric Antigen Receptor-Modified T Cells for Cancer
- (2013) Qing Zhang et al. CURRENT GENE THERAPY
- CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
- (2013) J Chu et al. LEUKEMIA
- Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells
- (2013) Hua Jiang et al. Molecular Oncology
- Effects of bortezomib in sensitizing human prostate cancer cell lines to NK-mediated cytotoxicity
- (2012) Wei Hu et al. ASIAN JOURNAL OF ANDROLOGY
- Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma
- (2012) Roniel Cabrera et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer
- (2012) Stephanie K. Bunt et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor
- (2012) Christiane Sahm et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
- (2011) C. U. Louis et al. BLOOD
- Gemcitabine enhances Wilms’ tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response
- (2011) Akitaka Takahara et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma
- (2011) Antonia Busse et al. EUROPEAN JOURNAL OF CANCER
- NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin
- (2011) Ruth Esser et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
- (2011) Razelle Kurzrock et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
- (2009) J. S. Ko et al. CLINICAL CANCER RESEARCH
- Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells
- (2009) Laurent Boissel et al. LEUKEMIA RESEARCH
- Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
- (2008) J. H. Finke et al. CLINICAL CANCER RESEARCH
- Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial
- (2008) S. Arai et al. CYTOTHERAPY
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
- (2008) Martin A Pule et al. NATURE MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started